LabGenius

LabGenius is a machine-learning-driven protein engineering company that discovers novel therapeutic antibodies. Its EVA discovery platform combines ML, automated wet-lab experimentation and robotics to systematically identify high-performing multispecific antibodies with non-intuitive designs that human designers would be unlikely to find. The company is progressing a wholly-owned pipeline of multispecific antibodies for solid tumours toward the clinic. Founded in 2012 and based in London, it raised a £35M Series B led by M Ventures (Merck's venture arm) in May 2024, bringing total funding to £58M.